Oppenheimer Issues Pessimistic Forecast for Zura Bio (NASDAQ:ZURA) Stock Price

Zura Bio (NASDAQ:ZURA) had its price target decreased by Oppenheimer from $19.00 to $17.00 in a research note published on Friday morning,Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

Several other analysts also recently issued reports on ZURA. Guggenheim reissued a “buy” rating and issued a $15.00 price target on shares of Zura Bio in a research report on Wednesday, March 26th. Chardan Capital reduced their price target on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Finally, HC Wainwright reissued a “buy” rating on shares of Zura Bio in a research report on Thursday, April 3rd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $14.33.

Zura Bio Stock Down 4.0%

Shares of ZURA stock opened at $1.21 on Friday. The company has a market cap of $82.73 million, a price-to-earnings ratio of -2.28 and a beta of 0.05. Zura Bio has a 52 week low of $0.97 and a 52 week high of $6.35. The firm has a 50 day moving average of $1.28 and a 200-day moving average of $2.08.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Zura Bio

A number of hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after acquiring an additional 7,828 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock worth $58,000 after acquiring an additional 9,379 shares during the last quarter. Bank of America Corp DE boosted its holdings in Zura Bio by 31.9% during the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after acquiring an additional 9,966 shares during the last quarter. Rhumbline Advisers boosted its holdings in Zura Bio by 37.3% during the 4th quarter. Rhumbline Advisers now owns 37,657 shares of the company’s stock worth $94,000 after acquiring an additional 10,231 shares during the last quarter. Finally, American Century Companies Inc. purchased a new position in Zura Bio during the 4th quarter worth $27,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.